Prucalopride
Active ingredient: Prucalopride Succinate
In short: Prucalopride tablet is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
What is Prucalopride used for?
Prucalopride tablet is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Prucalopride dosage
Prucalopride tablets can be taken with or without food. The recommended dosage by patient population is shown in Table 1.
Table 1: Recommended Dosage Regimen and Dosage Adjustments by Population
Population with CIC | Recommended Oral Dose Regimen
Adults | 2 mg once daily
Patients with severe renal impairment (creatinine clearance (CrCL) less than 30 mL/min) . | 1 mg once daily
How to take Prucalopride — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information)
Suicidal Ideation and Behavior: Inform patients, their caregivers, and family members that suicidal ideation and behavior, self-injurious ideation as well as new onset or worsening depression have been reported in patients treated with prucalopride tablets. Advise them to be aware of any unusual changes in mood or behavior, new onset or worsening of depression, or the emergence of suicidal thoughts or behavior. Instruct patients, caregivers, and family members to discontinue prucalopride tablets immediately and contact their healthcare provider if any of these symptoms occur .
Storage
Advise patients to keep prucalopride tablets in the original container to protect from moisture.
All trademarks are the property of their respective owners.
Distributed by:
ANI Pharmaceuticals, Inc.
Baudette, MN 56623
Issued: 07/2026
LB4664-05
For more information, call 1-855-204-1431.
Warnings & precautions
Do not take this medicine if: Prucalopride tablets are contraindicated in patients with:
A history of hypersensitivity to prucalopride. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed .
Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum.
In clinical trials, suicides, suicide attempts, and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting prucalopride tablets .
A causal association between treatment with prucalopride tablets and an increased risk of suicidal ideation and behavior has not been established.
Monitor all patients treated with prucalopride tablets for new onset or worsening of depression or the emergence of suicidal thoughts and behaviors. Counsel patients, their caregivers, and family members of patients to be aware of any unusual changes in mood or behavior and alert the healthcare provider. Instruct patients to discontinue prucalopride tablets immediately and contact their healthcare provider if they experience any of these symptoms.
Prucalopride side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below represent 2,530 patients (1,251 received prucalopride tablets 2 mg once daily and 1,279 received placebo) with CIC from 6 double-blind, placebo-controlled clinical trials of 12 weeks to 24 weeks in duration. In these trials overall, patients were primarily female (76%) and white (76%). The mean age was 47 years (range 17 to 95 years) .
Common Adverse Reactions
Table 2 below summarizes the incidence (%) of common adverse reactions occurring in at least 2% of patients with CIC receiving either 2 mg of prucalopride tablets once daily or placebo and at an incidence greater than in the placebo group from the six double-blind placebo-controlled trials described above.
Table 2: Common Adverse Reactions* in Double-Blind Placebo-Controlled Trials of CIC of at least 12 Weeks Duration
Adverse Reaction | Prucalopride Tablets
2 mg Once Daily
N=1251
â€
% | Placebo
N=1279
%
Headache | 19 | 9
Abdominal pain‡ | 16 | 11
Nausea | 14 | 7
Diarrhea | 13 | 5
Abdominal distension | 5 | 4
Dizziness | 4 | 2
Vomiting | 3 | 2
Flatulence | 3 | 2
Fatigue | 2 | 1
* Reported in ≥2% of patients receiving prucalopride tablets and a rate higher than patients receiving placebo. …
About this medicine
Prucalopride tablets for oral use contain prucalopride succinate, a dihydrobenzofurancarboxamide that is a serotonin type 4 (5-HT4) receptor agonist. The IUPAC name is: 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydrobenzofuran-7-carboxamide succinate.
The molecular formula is C18H26ClN3O3.C4H6O4 and the molecular weight is 485.96. The structural formula is:
Prucalopride succinate is a white to almost white powder. It is highly soluble in acidic aqueous media and alkaline aqueous media up to a pH of approximately 9.
Each 1-mg film-coated tablet of prucalopride contains 1 mg of prucalopride (equivalent to 1.32 mg prucalopride succinate), and the following inactive ingredients: colloidal silicon dioxide, anhydrous lactose, magnesium stearate, and microcrystalline cellulose. The coating for the 1-mg tablet contains hypromellose, lactose monohydrate, polyethylene glycol 3000, titanium dioxide, and triacetin. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6d82dfbd-f171-4045-9f7a-268e189a658a. Read the full official label on DailyMed.
Related medicines
Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate